Compared to Estimates, Teleflex (TFX) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2025, Teleflex (TFX) reported revenue of $780.89 million, up 4.2% over the same period last year. EPS came in at $3.73, compared to $3.42 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $771.12 million, representing a surprise of +1.27%. The company delivered an EPS surprise of +11.01%, with the consensus EPS estimate being $3.36.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Geographic Revenues- Americas: $525.7 million versus $483.49 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +23.2% change.Geographic Revenues- EMEA: $166.2 million versus the eight-analyst average estimate of $162.22 million.Geographic Revenues- Asia: $89 million versus the eight-analyst average estimate of $96.61 million.Net Revenues- Interventional: $170 million versus $153.83 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a +20.4% change.Net Revenues- Interventional Urology: $76.4 million compared to the $76.09 million average estimate based on 12 analysts. The reported number represents a change of -8.1% year over year.Revenues- OEM (Original Equipment Manufacturer and Development Services): $78.7 million versus the 12-analyst average estimate of $76.34 million. The reported number represents a year-over-year change of -11.4%.Net Revenues- Vascular Access: $185.5 million versus the 12-analyst average estimate of $189.93 million. The reported number represents a year-over-year change of +2.4%.Net Revenues- Anesthesia: $96.4 million versus $103.9 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a -6% change.Net Revenues- Other: $59.9 million versus the 12-analyst average estimate of $56.23 million. The reported number represents a year-over-year change of +43.7%.Net Revenues- Surgical: $114 million versus the 12-analyst average estimate of $114.77 million. The reported number represents a year-over-year change of +2.4%.View all Key Company Metrics for Teleflex here>>>Shares of Teleflex have returned -6.3% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.One Big Gain, Every Trading DayTo help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teleflex Incorporated (TFX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks